Factors associated with the presence of glutamic acid decarboxylase and islet antigen-2 autoantibodies in patients with long-standing type 1 diabetes

Diabetes and Metabolism

Volumn 39, Issue 3, 2013, Pages 244-249

  Wilmot Roussel, H ^a   Levy D J ^a   Carette, C ^a   Caillat Zucman, S ^b   Boitard, C ^a,b,c   Timsit, J ^a   Dubois Laforgue, D ^a,c  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Classification; GAD antibodies; IA 2 antibodies; Persistency; Type 1 diabetes

Indexed keywords

GLUTAMATE DECARBOXYLASE; HLA DRB1 ANTIGEN; ISLET ANTIGEN 2 AUTOANTIBODY; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HYPERGLYCEMIA; IMMUNOLOGICAL PARAMETERS; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STOMACH PARIETAL CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84878764074     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.01.002     Document Type: Article

References (17)

1. Roep B.O., Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2012, 2:a007781.
2. Bingley P.J. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010, 95:25-33.
3. 65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia 1997, 40:95-99.
4. Murphy R., Ellard S., Hattersley A.T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:200-203.
5. Savola K., Sabbah E., Kulmala P., Vähäsalo P., Ilonen J., Knip M. Autoantibodies associated with Type 1 diabetes mellitus persist after diagnosis in children. Diabetologia 1998, 41:1293-1297.
6. Hermitte L., Atlan-Gepner C., Mattei C., Dufayet D., Jannot M.F., Christofilis M.A., et al. Diverging evolution of anti-GAD and anti-IA-2 antibodies in long-standing diabetes mellitus as a function of age: no association with complications. Diabet Med 1998, 15:586-591.
7. Decochez K., Tits J., Coolens J.L., Van Gaal L., Krzentowski G., Winnock F., et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 2000, 23:838-844.
8. Zanone M.M., Catalfamo E., Pietropaolo S.L., Rabbone I., Sacchetti C., Cerutti F., et al. Glutamic Acid Decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual β-cell function and glycemic control in young type 1 diabetic patients. Metabolism 2003, 52:25-29.
9. Wenzlau J.M., Walter M., Gardner T.J., Frisch L.M., Yu L., Eisenbarth G.S., et al. Kinetics of post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010, 95:4712-4719.
10. Keenan H.A., Sun J.K., Levine J., Doria A., Aiello L.P., Eisenbarth G., et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010, 59:2846-2853.
11. Tridgell D.M., Spiekerman C., Wang R.S., Greenbaum C.J. Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the Type 1 Diabetes Genetics Consortium database. Diabetes Care 2011, 34:988-993.
12. Törn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Participating Laboratories. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
13. Wang L., Lovejoy N.F., Faustman D.L. Persistence of prolonged C-peptide production in type 1 diabetes as measures with an ultrasensitive C-peptide assay. Diabetes Care 2012, 35:465-470.
14. Faustman D.L., Wang L., Okubo Y., Burger D., Ban L., Man G., et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 2012, 7:e41756.
15. Mallone R., Brezar V., Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol 2011, 2011:513210.
16. Bellanné-Chantelot C., Lévy D.J., Carette C., Saint-Martin C., Riveline J.P., Larger E., et al. Clinical characteristics and diagnostic criteria of Maturity-Onset Diabetes of the Young (MODY) due to molecular anomalies of the HNF1A Gene. J Clin Endocrinol Metab 2011, 93:E1346-E1351.
17. McDonald T.J., Colclough K., Brown R., Shields B., Shepherd M., Bingley P., et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 2011, 28:1028-1033.